Multiplex Assay Kit for Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay)

Apo-C3; APOCIII; APOC-III

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 87-95 90
EDTA plasma(n=5) 95-104 101
heparin plasma(n=5) 79-96 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 85-92% 78-93% 89-103% 90-98%
EDTA plasma(n=5) 84-103% 80-101% 94-102% 81-90%
heparin plasma(n=5) 94-103% 82-94% 91-98% 79-104%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:APOC3) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Atherosclerosis Up-reCavia (Guinea pig )lation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure – A possible link between circulating PCSK9 and triacylglycerol concentrations Pubmed:26978583
The Journal of Lipid Research Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism Pubmed:27040449
Journal of Chromatography A Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis S0021967317311858
J Transl Med Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans 33407555
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPB890Ra01 Recombinant Apolipoprotein C3 (APOC3) Positive Control; Immunogen; SDS-PAGE; WB.
PAB890Ra01 Polyclonal Antibody to Apolipoprotein C3 (APOC3) WB; IHC; ICC; IP.
LAB890Ra71 Biotin-Linked Polyclonal Antibody to Apolipoprotein C3 (APOC3) WB; IHC; ICC.
LAB890Ra81 FITC-Linked Polyclonal Antibody to Apolipoprotein C3 (APOC3) WB; IHC; ICC; IF.
MAB890Ra21 Monoclonal Antibody to Apolipoprotein C3 (APOC3) WB; IHC; ICC; IP.
SEB890Ra ELISA Kit for Apolipoprotein C3 (APOC3) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB890Ra Multiplex Assay Kit for Apolipoprotein C3 (APOC3) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.